Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability.
• FXS is characterized by intellectual disability, autism, hyperactivity, and epilepsy.

Purpose of the Study:

• To review the literature on synaptic dysfunction in FXS.
• To analyze hypotheses explaining synaptic dysregulation in FXS.

Main Methods:

• Literature review of scientific evidence.
• Analysis of hypotheses linking research to clinical trials.

Main Results:

• Synaptic dysfunction in FXS disrupts the excitation-inhibition balance.
• This dysregulation affects cognition, learning, memory, and social behavior.
• Translating FXS research from animal models to clinical treatments has been largely unsuccessful.

Conclusions:

• Synaptic dysfunction is a key factor in FXS.
• Despite extensive research, effective pharmacological treatments for FXS remain elusive.
• Further investigation into FXS pathophysiology is needed.